AVEXA REPORTS DATA FROM AVX7 54 STUDY
Avexa has reported its progress with the ongoing AVX-201 Phase IIb trial and its intentions to ramp up preparations towards Phase III development.
The AVX-201 Phase IIb trial is a blinded study of the efficacy of AVX754 in the treatment of drug-resistant HIV infection. Although the study is blinded as to the exact treatment an individual receives, no person enrolled into the trial to date has experienced any adverse effects attributed to the study treatment. No subjects have been withdrawn from the study, and the first subject has completed six months of dosing.